Remove 2022 Remove Pharma Remove Pharmacology
article thumbnail

2022 in review: Drug development milestones for tropical diseases

Pharmaceutical Technology

Spearheaded by collaborations between non-profit groups and pharma players, new treatments are edging closer to late-stage trials in malaria and neglected tropical diseases such as sleeping sickness. Pharmaceutical Technology lists some of the top events in the tropical disease arena in 2022.

article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex. Looking back at 2023 , AI for drug discovery saw both wins and losses.

Pharma 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lipid Nanoparticles Immunogenicity & Toxicity | December 6-8, 2022

pharmaphorum

The highly anticipated Lipid Nanoparticle Immunogenicity & Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology , immunogenicity , bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma 110
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

There is a clear trend away from developing pharmacological therapies targeting opioid receptors” There is a clear trend away from developing pharmacological therapies targeting opioid receptors. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience. References Cruccu G, Truini A.

Medicine 102
article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

Timely and accurate diagnosis is critical to maximize the efficacy of available interventions – but for most individuals, the diagnostic journey remains long, complex and costly (Alzheimer’s Disease International, 2021; Chiari, 2022; Juganavar, 2023). In 2022, the U.S. 2024; Quanterix, 2024). Food and Drug Administration, n.d.),

article thumbnail

Tapping into digital therapeutics to improve neurological outcomes

Pharmaceutical Technology

Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Securing reimbursement for digital therapeutics also continues to impede its uptake.